Anti Covid pill, Merck: “Reduced deaths and hospitalizations by 50%, soon request ok to Fda”

Merck accelerates the process to bring the Covid-19 treatment pill to market and challenges Pfizer. The pharmaceutical company has in fact published the first results of the trial which showed a 50% reduction in the risk of hospitalization and deaths of people infected with the coronavirus. Merck and partner Ridgeback Biotherapeutics have announced that they will soon ask the US FDA to authorize emergency use of the drug, molnupiravir, in the United States as soon as possible.